2-[1-(4-chloro-benzyl)-1H-indole-3-carbonyl]-3H-imidazole-4-carboxylic acid | 501659-88-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-[1-(4-chloro-benzyl)-1H-indole-3-carbonyl]-3H-imidazole-4-carboxylic acid
• 英文别名: 2-[1-[(4-chlorophenyl)methyl]indole-3-carbonyl]-1H-imidazole-5-carboxylic acid
• CAS: 501659-88-7
• 化学式: C₂₀H₁₄ClN₃O₃
• 分子量: 379.802
• InChiKey: PESHELFQVAFAKZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  88
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-[1-(4-chloro-benzyl)-1H-indole-3-carbonyl]-3H-imidazole-4-carboxylic acid 、 乙胺 在 4-二甲氨基吡啶 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 生成 2-[1-[(4-chlorophenyl)methyl]indole-3-carbonyl]-N-ethyl-1H-imidazole-5-carboxamide
  参考文献：
  名称：

  Conjugated indole-imidazole derivatives displaying cytotoxicity against multidrug resistant cancer cell lines

  摘要：

  We report herein the SAR studies of a series of indole-imidazole compounds. that demonstrate substantial in vitro anti-proliferative activities against cancer cell lines, including multidrug resistance (MDR) phenotypes. The in vitro cytotoxic effects have been demonstrated across a wide array of tumor types, including hematologic and solid tumor cell lines of various origins (e.g., leukemia, breast, colon, and uterine). (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.07.020
• 作为产物：
  描述：

  [1-(4-Chloro-benzyl)-1H-indol-3-yl]-[4-(4,4-dimethyl-4,5-dihydro-oxazol-2-yl)-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazol-2-yl]-methanol 在 盐酸 、 manganese(IV) oxide 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 2.0h， 生成 2-[1-(4-chloro-benzyl)-1H-indole-3-carbonyl]-3H-imidazole-4-carboxylic acid
  参考文献：
  名称：

  Conjugated indole-imidazole derivatives displaying cytotoxicity against multidrug resistant cancer cell lines

  摘要：

  We report herein the SAR studies of a series of indole-imidazole compounds. that demonstrate substantial in vitro anti-proliferative activities against cancer cell lines, including multidrug resistance (MDR) phenotypes. The in vitro cytotoxic effects have been demonstrated across a wide array of tumor types, including hematologic and solid tumor cell lines of various origins (e.g., leukemia, breast, colon, and uterine). (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.07.020

文献信息

• 2-Aroylimidazole compounds for treating cancer
  申请人：SBR Pharmaceuticals Corp.

  公开号：US20030096836A1

  公开（公告）日：2003-05-22

  Disclosed is a compound represented by Structural Formula (I): 1 R 1 is a substituted or unsubstituted 2-imidazolyl group which is optionally fused to a substituted or unsubstituted aryl group. Z 1 is ═O, ═S, ═NOR 11 , or ═NR 11 . R is represented by a Structural Formula selected from (II)-(VII): 2 The variables in Structural Formulas (II)-(VII) are described below.

  揭示的化合物由结构式（I）表示：1R1是一个取代或未取代的2-咪唑基团，可选择地与取代或未取代的芳基团融合。Z1是═O、═S、═NOR11或═NR11。R由从（II）到（VII）中选择的结构式表示。结构式（II）到（VII）中的变量如下描述。
• 2-aroylimidazole compounds for treating cancer
  申请人：Synta Pharmaceuticals Corp.

  公开号：US06743919B2

  公开（公告）日：2004-06-01

  Disclosed is a compound represented by Structural Formula (I): R1 is a substituted or unsubstituted 2-imidazolyl group which is optionally fused to a substituted or unsubstituted aryl group. Z1 is ═O, ═S, ═NOR11, or ═NR11. R is represented by a Structural Formula selected from (II)-(VII): The variables in Structural Formulas (II)-(VII) are described below.

  本发明涉及一种化合物，其结构式表示为（I）：其中R1表示取代或未取代的2-咪唑基团，该基团可以选择性地与取代或未取代的芳基团融合。Z1表示═O、═S、═NOR11或═NR11。R由以下结构式中的一种所表示：（II）-（VII）。结构式（II）-（VII）中的变量如下所述。
• 2-AROYLIMIDAZOLE COMPOUNDS FOR TREATING CANCER
  申请人：Synta Pharmaceuticals Corporation

  公开号：EP1427413A2

  公开（公告）日：2004-06-16
• US6743919B2
  申请人：——

  公开号：US6743919B2

  公开（公告）日：2004-06-01
• US7081466B2
  申请人：——

  公开号：US7081466B2

  公开（公告）日：2006-07-25